4 Result(s)
within
Gerardo Rosati
Medicine & Public Health
Cancer Research
-
Article
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial
EOX (epirubicin, oxaliplatin, and capecitabine) is one of the standard regimens for metastatic or locally advanced gastric cancer (GC). A new combination based on fractional docetaxel (low-TOX) has been develo...
-
Article
Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer
There is no consensus on the use of cetuximab in elderly patients with metastatic colorectal cancer. To this end, a survey was carried in 17 Italian oncology centers.
-
Article
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world
Although second-line therapy is often considered for advanced gastric cancer patients, the optimal candidates are not well defined.
-
Article
XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study
The addition of bevacizumab to oxaliplatin-based chemotherapy significantly improved progression-free survival (PFS) in patients with metastatic colorectal cancer (CRC). An increased risk of arterial thromboem...
